Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.88 |
| ▸ | DRD2 | P14416 | 2/20 | 0.88 |
| ▸ | DRD3 | P35462 | 2/20 | 0.88 |
| ▸ | HTR7 | P34969 | 3/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | HTR1B | P28222 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10546291 | 0.90 | HTR1A (0.86) | HTR1ADRD2DRD3HTR7ADRA1B | |
| SCHEMBL15105697 | 0.85 | HTR7 (0.70) | HTR1ADRD2DRD3HTR7ADRA1B | |
| SCHEMBL10542355 | 0.84 | HTR7 (0.98) | HTR1ADRD2DRD3HTR7ADRA1B | |
| SCHEMBL875808 | 0.84 | HTR7 (0.69) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL875833 | 0.83 | HTR1A (0.62) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL875128 | 0.81 | HTR1A (0.60) | HTR1ADRD2DRD3HTR7ADRA1B | |
| SCHEMBL22001855 | 0.80 | DRD2 (0.86) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL14761823 | 0.80 | HTR7 (0.79) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL14761592 | 0.79 | DRD2 (0.65) | HTR1ADRD2DRD3HTR7 | |
| SCHEMBL31094938 | 0.78 | DRD2 (0.63) | HTR1ADRD2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723759-B1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2024-01-10 | — | — | EP | claimed |
| EP-3723759-A2 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A. (BR) | 2020-10-21 | — | — | EP | claimed |
| CN-111601600-A | Treatment of post-traumatic syndrome disorder | 艾奇实验室制药有限公司 | 2020-08-28 | — | — | CN | claimed |
| WO-2019113668-A2 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A (BR) | 2019-06-20 | — | — | WO | claimed |
| US-9169218-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHE LABORATORIOS FARMACEUTICOS S.A. (BR) | 2015-10-27 | — | — | US | claimed |
| EP-2619187-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMAC UTICOS S A (BR) | 2015-03-04 | — | — | EP | claimed |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHE LABORATORIOS FARMACEUTICOS S.A., ATC Trustees Abbot Building, 2nd FLoor, Road Town (BR) | 2014-11-13 | — | — | US | claimed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | claimed |
| EP-3723759-B1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2024-01-10 | — | — | EP | disclosed |
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2021-11-04 | — | — | US | disclosed |
| US-20210221774-A1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A (BR) | 2021-07-22 | — | — | US | disclosed |
| US-20210221774-A1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A (BR) | 2021-07-22 | — | — | US | disclosed |
| US-20210221774-A1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A (BR) | 2021-07-22 | — | — | US | disclosed |
| EP-3723759-A2 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | Aché Laboratórios Farmacêuticos S.A. (BR) | 2020-10-21 | — | — | EP | disclosed |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHE LABORATORIOS FARMACEUTICOS S.A., ATC Trustees Abbot Building, 2nd FLoor, Road Town (BR) | 2014-11-13 | — | — | US | disclosed |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2014-10-09 | — | — | US | disclosed |
| US-8735578-B2 | Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2014-05-27 | — | — | US | disclosed |
| EP-2619187-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | Aché Laboratórios Farmacêuticos S.A. (BR) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ INTERNATIONAL (BVI) LTD. (VG) | 2013-07-18 | — | — | US | disclosed |
| WO-2012037634-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338674-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR2A, HTR5A, HTR2C | HTR1A 4/4885DRD2 20/4885DRD3 56/4885 |
| US-20140303179-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR1A | HTR1A 3/4885DRD2 22/4885DRD3 54/4885 |
| US-20140336199-A1 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors | HTR5A, HTR2A, HTR2C | HTR1A 4/4885DRD2 22/4885DRD3 55/4885 |
| US-20130184286-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS | HTR5A, HTR2A, HTR2C | HTR1A 4/4885DRD2 22/4885DRD3 56/4885 |
| US-20210221774-A1 | TREATMENT OF POST-TRAUMATIC SYNDROME DISORDER | HTR5A, HTR3C, FKBP5 | HTR1A 58/4885DRD2 55/4885DRD3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.